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Dynamic changes in purine catabolism in patients with acute 
coronary syndrome that underwent percutaneous 
coronary intervention 
 
Abstract 
Background: Cardiovascular diseases are global problems. They are causes of death in 
about 43% of people worldwide and may become the most widespread reason of death by 
2020. The prognosis is directly dependent to immediate diagnosis and on time treatment. 
Introduction of new biochemical markers as the early diagnosis of complications after 
coronary revascularization is very important in this period. Herein, we assayed the changes 
of purine catabolites in patients with acute coronary syndrome (ACS) before and after 
percutaneous coronary intervention (PCI) in comparison with control group. 
Methods: Thirty five ACS patients (20 males and 15 females) were included (57±17 years 
old) in the study. The determination of intermediates of purine catabolism as guanine, 
hypoxanthine (GCS), adenine, xanthine (Kc) and uric acid (MK) were assayed before and 
3 days after PCI. Conditionally, 35 healthy-matched persons were included in the control 
group. Purine catabolites were determined in plasma through the method of Oreshnikov 
E.V (2008). 
Results: In ACS patients, prior to PCI, there was a tendency to increase the concentration 
of guanine (P=0.001), hypoxanthine (P=0.002) adenine (P=0.0003), xanthine 
(P=0.000003) and uric acid (P=-0.000001) relative to the upper limits of normal ranges. 
And on the third day after PCI, there was the second tendency to increase the levels of 
guanine (P=0.000001), hypoxanthine (P=0.000001) adenine (P=0.0000001), xanthine 
(P=0.000001) and uric acid (P=0.0000001) relative to upper limits of normal ranges. 
Conclusion: Increment of plasma purine catabolites can be a marker of inflammation and 
instability of coronary artery plaques and may be used as a restenosis marker in patients 
with history of PCI. 
Keywords: Coronary heart disease, Acute coronary syndrome (ACS), Purine catabolites, 
Uric acid, Percutaneous coronary intervention (PCI). 
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Cardiovascular diseases are not only big medical problems but also have social 
consequences. Ischemic heart diseases (IHD) are cause of death in about 43%of people 
worldwide, but according to predictions, it might become the most widespread cause of 
death by 2020 (1). Today in Kazakhstan, cardiovascular diseases are the cause of death in 
one-third of people, and as well in the previous decade, the morbidity of IHD has increased 
5-7 times (2). In the development and progression of coronary heart diseases, some factors 
have great roles such as increased population age, unusual habits, nutrition and genetic 
factors (3). The prognosis is directly related to immediate diagnosis, prevention of 
complications and urgent myocardial revascularization (4).  
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There are some risks to develop complications in spite of 
the improvement in modern interventional cardiology and 
cardiac surgery. More often these complications resulted in 
activation and progression of inflammatory processes in 
atherosclerotic or PCI zones (5).  
Evaluation of the role of extracellular purines in the 
development of various pathological conditions is a new 
tendency in modern biochemistry. Adenine and guanine are 
the basic purine bases. Xanthine and hypoxanthine are their 
catabolites, and uric acid is the final product of purine 
catabolism. Purines have influence on the cells with 
activation of specific receptors on the cell membrane. Such 
receptors are in majority number in blood vessels, heart and 
other organs in the body (6). In particular, the different types 
of Р2Y-receptors are revealed in progression of heart failure. 
It determines their role in myocardial function (7). On the 
other hand, hyperuricemia initiates aseptic inflammation (8). 
Marked hyperuricemia unfavorably affects the hemostatic 
system and vascular wall (9).  
The aim of this research was to assess the dynamic 
changes of purine catabolites in blood plasma of patients 
with acute coronary syndrome before and after percutaneous 
coronary intervention.  
 
 
Methods 
35 ACS patients (17 females, 18 males) were included 
(57±17 years old)in the study. These patients with acute 
coronary syndrome were admitted to the Emergency Cardiac 
Department of Karaganda City Hospital. Diagnosis of ACS 
was done by expert cardiologists via history taking, physical 
examination, electrocardiography, echocardiography, cardiac 
biomarkers like troponin I and T, and coronary angiography. 
Levels of plasma purine concentrations were assayed before 
and 3 days after PCI. The patients with diabetes mellitus, 
chronic obstructive pulmonary disease, gout, chronic 
rheumatic heart disease with formation of valvular defects, 
cancer, as well as patients with renal dysfunction were 
excluded.  
Conditionally 35 healthy matched persons (20 females, 
15 males), (55±5 years old) were included in the control 
group. Determination of intermediates of purine catabolism 
as guanine, hypoxanthine (GCS), adenine, xanthine (Kc) and 
uric acid (MK) were assayed in plasma of all cases and 
control group. Venous blood was used as a research material, 
and the metabolites of purine were determined by the 
method of Oreshnikov E.V. et al. (2008) (5). Concentration 
of purine catabolites was expressed in terms of extinction 
(unit of ext.), and the concentration of uric acid in μmol / l. 
Statistical analysis of the data was performed using the 
software package STATISTICA Version 8.0 based on the 
computational methods recommended for biology and 
medicine. The analysis of the obtained data included the 
calculation of average arithmetic variation series (M) and its 
error (m). Reliability of observed differences was determined 
by paired t-test method using the t-coefficient of Student. 
 
 
Results 
We evaluated the purine catabolites in patients with acute 
coronary syndrome before and on the 3rd day after PCI in 
comparison with the control group, and the statistical 
significant differences were revealed (table 1). 
 
Table 1. Mean values (standard deviation) of purine 
metabolites in patients with ACS before and on the 3rd 
day after PCI compared with control group. 
 
 Mean(standard 
deviation) 
Before PCI 
Mean(standard 
deviation) 
3 days after 
PCI 
Mean(standard 
deviation) 
control group 
Guanine 0.47 (0.53)* 1.33 (0.96)* 0.14 (0.04)* 
Hypoxanthine 0.42 (0.54)* 1.24 (0.99)* 0.12 (0.04)* 
Adenine 0.28 (0.26)* 0.84 (0.77)* 0.1 (0.04)* 
Xanthine 0.26 (0.12)* 0.45 (0.29)* 0.14 (0.06)* 
Uric acid 0.28 (0.09)* 0.36 (0.14)* 0.16 (0.05)* 
*Statistical significant differences via a student t-test for 
independent samples (р<0.05) 
 
An apparent increment was observed in plasma 
concentrations of guanine, hypoxanthine, adenine, xanthine 
and uric acid in patients compared the with control group. In 
plasma samples taken from patients with acute coronary 
syndrome prior to PCI, there was a tendency to increase 
concentration of guanine (p-0.001), hypoxanthine (p-0.002) 
adenine (p-0.0003), xanthine (p-0.000003) and uric acid  
(p-0.000001) relative to the physiologic upper limits. In 
plasma samples taken from the same patients on the third 
day after PCI, there was also second tendency to increase the 
content of guanine (p-0.000001), hypoxanthine (p-0.000001) 
adenine (p-0.0000001), xanthine (p-0.000001) and uric acid 
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(p-0.0000001) relative to physiologic upper limits too. In 
comparison, there was a tendency to increase their 
concentration on the 3
d
 day after PCI. The results are shown 
in figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Dynamic changes in plasma purine catabolites before and after PCI (stenting) in ACS patients 
 
Discussion  
 Marked tendency to the elevation of purine catabolites in 
plasma of patients with acute coronary syndrome may be the  
result of various mechanisms. First of all, this can be due to  
 
entry into blood as result of cell damage during myocardial 
ischemia. Another reason may be a violation of the reverse 
transport of purine nucleotides and its intermediates into 
cells, which is caused by a violation of their capture by 
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specific receptors on cell membranes. In addition, the 
development of acute coronary syndrome is preceded by 
processes leading to atherosclerotic plaque to become 
unstable. A similar plaque related to infarction, more often 
has non-dramatic character. That is why it does not lead to 
significant disruption of the coronary blood flow (2). 
Unstable plaque is abundantly infiltrated by inflammatory 
cells, which contribute to the damage of fibrous cap. As a 
result of atherosclerotic plaque rupture or of its erosion, 
platelet aggregation inducers (collagen and other substances) 
and tissue factor inducers are released; and these lead to the 
start of thrombogenesis process. In the process of 
inflammation, a large number of purine metabolites are 
released into the extracellular space by neutrophils, 
endothelial cells and activated macrophages. It explains an 
increase in the concentration of purine catabolites in plasma. 
ADP, which is released by platelets, also has the great 
contribution into the elevation of the level of extracellular 
purines after dephosphorization (10). Significant increase in 
the concentration of purine catabolites after PCI may be due 
to the development of aseptic inflammation in the stented 
area, which is also accompanied by the migration of 
inflammatory factors to this part of coronary artery (8). 
Adverse effects of hyperuricemia on hemostatic system 
and vascular wall were established (11). Larina V.N. et al. in 
their scientific investigation in 2016, pointed to the role of 
chronic tissue hypoxia in cardiovascular diseases and in the 
development of endothelial dysfunction, which in turn leads 
to an increment in the activity of xanthine oxidase enzyme 
and the accumulation of uric acid as the final product of 
purine metabolism, in the plasma (7).  
 In this research, we evaluated complete spectrum of 
intermediate purine metabolites in the blood plasma of 
patients with acute coronary syndrome before and after PCI. 
The results of our investigation showed that in patients 
with acute coronary syndrome before and on the 3rd day 
after PCI, the elevation of all purine catabolites in blood 
plasma were present, with marked elevation in metabolites 
of initial stage of catabolism of purines: adenine, guanine 
and hypoxanthine. It may be the result of low activity of the 
specific ferment – xanthine oxidase.   
Some researchers like Don E Farthing et al. describe the 
significant contribution of necrosis and lysis of 
cardiomyocytes in the elevation of extracellular 
concentration of intermediates of purine metabolism. This 
pathological process is associated with the next mechanisms 
(12).  For normal function of cardiac muscle, it is necessary 
to use much amount of ATP produced by intracellular 
mitochondria in cardiomyocytes. About 80% of all ATP in 
myocardium is produced by such organelles using aerobic 
oxidative phosphorylation in electron transport chain. The 
normal function of this process is associated with sufficient 
number of normally functioning cardiomyocytes under 
sufficient oxygenation. Therefore, the development of acute 
ischemia as the result of insufficiency of coronary arteries, 
lead to severe metabolic disturbances in the affected 
myocardium (7). 
At the onset of cardiac ischemia, the high energy 
phosphates (creatine phosphate and ATP) are rapidly 
depleted and heart tissues would lose 65% of their ATP 
contents within 15 minutes of complete ischemia (13). Such 
ischemic events in turn mobilize ATP breakdown cascade 
that leads to cellular accumulation of ATP catabolic by-
products, including adenosine diphosphate (ADP), adenosine 
monophosphate (AMP), and activates normally dormant 
enzymes, such as 5′-nucleotidase, adenosine deaminase, 
purine nucleoside phosphorylase, and xanthine oxidase, 
which sequentially catabolize AMP into adenosine, inosine, 
hypoxanthine, xanthine, and uric acid. Upon reperfusion of 
the heart with oxygenated blood or perfusate, xanthine 
oxidase and xanthine dehydrogenase convert hypoxanthine 
to xanthine and uric acid (14). 
Furthermore it is known that inosine and hypoxanthine 
are the small molecules with molecular mass about 268 
Dalton for inosine and 136 Dalton for hypoxanthine. This 
fact facilitates their rapid passive diffusion to the plasma 
from damaged cardiomyocytes (15). Thus, the described 
mechanisms explain the statistically significant elevation of 
extracellular concentration of purine catabolites in patients 
with acute coronary syndrome. 
The next important moment determined during our 
investigation, is the tendency to a significant increase in the 
concentration of all purine catabolites on the 3rd day after 
PCI. What is the reason of such changes?  
Ghaemi-Oskouie, et al. (16), connected with estimation 
of the role of uric acid as an endogenous danger signal in 
immunity and inflammation, determined that uric acid has 
been identified as an endogenous adjuvant that drives 
immune responses in the absence of microbial stimulation. 
Because uric acid is an ubiquitous metabolite that is 
produced in high quantities upon cellular injury, the 
ramifications of its effects may be considered. Uric acid 
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crystals also have been shown to trigger interleukin-1β–
mediated inflammation via activation of NOD-like receptor 
protein (NLRP) 3 inflammasome, a multimolecular complex 
whose activation appears to be central to many pathological 
inflammatory conditions (17). 
In other studies (10, 18), the authors proved that 
hyperuricemia may act as the initiator of aseptic 
inflammatory reactions in various tissues including the 
myocardium and endocardium. As a result, based on many 
researches, considering the possible damage to intima of 
coronary artery during PCI, the development of aseptic 
inflammation in the vascular wall leads to endothelial 
dysfunction and an increase of extracellular concentration of 
purines, including uric acid. In its turn, hyperuricemia will 
also contribute to stimulation of inflammatory process, 
which can provoke progression of the atherosclerotic process 
in the stented area, the formation of neointima and in-stent 
restenosis as final result. 
In conclusion, the analysis of obtained data shows the 
need to further studies about extracellular purine 
involvement in the development and progression of coronary 
heart disease. In the case of acute coronary syndrome, purine 
catabolites act as the so-called "anxiety molecules". 
Elevation of their concentration signals cellular damage of 
the vascular endothelium under the situation of severe 
hypoxia. Significant increase in their concentration after PCI 
may be the marker of an inflammatory reaction in the 
endothelium of the coronary vessels due to the damage of 
plaque during PCI. It may provoke further progression of the 
inflammatory processes after coronary revascularization and 
contribute to the development of restenosis of vessel. 
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